Unique ID issued by UMIN | UMIN000004333 |
---|---|
Receipt number | R000005192 |
Scientific Title | Phase I study of peptide vaccination with GM-CSF for unresectable hepatocellular carcinoma |
Date of disclosure of the study information | 2010/10/06 |
Last modified on | 2012/10/31 15:52:46 |
Phase I study of peptide vaccination with GM-CSF for unresectable hepatocellular carcinoma
Phase I study of peptide vaccination with GM-CSF for unresectable hepatocellular carcinoma
Phase I study of peptide vaccination with GM-CSF for unresectable hepatocellular carcinoma
Phase I study of peptide vaccination with GM-CSF for unresectable hepatocellular carcinoma
Japan |
Hepatocellular carcinoma
Hepato-biliary-pancreatic surgery |
Malignancy
NO
The aim of this study is to assess the safety and clinical responses on peptide vaccination with GM-CSF for unresectable hepatocellular carcinoma.
Safety
Exploratory
Phase I
Assessment of safelty
Assessment of clinilal responses
Interventional
Parallel
Non-randomized
Open -no one is blinded
Dose comparison
3
Treatment
Vaccine |
Patients will be vaccinated once a week for eight weeks of a treatment cycle. On each vaccination day, VEGFR1, VEGFR2, GPC3 peptide(2mg) mixed with GM-CSF(10microgram) and Montanide ISA-51 will be administered by subcutaneous injection.
Patients will be vaccinated once a week for eight weeks of a treatment cycle. On each vaccination day, VEGFR1, VEGFR2, GPC3 peptide(2mg) mixed with GM-CSF(25microgram) and Montanide ISA-51 will be administered by subcutaneous injection.
Patients will be vaccinated once a week for eight weeks of a treatment cycle. On each vaccination day, VEGFR1, VEGFR2, GPC3 peptide(2mg) mixed with GM-CSF(50microgram) and Montanide ISA-51 will be administered by subcutaneous injection.
20 | years-old | <= |
80 | years-old | > |
Male and Female
1.HLA-A*2402 positive patients with clinically or pathologically diagnosed unresectable hepatocellular carcinoma.
2.Age between 20 to 80
3.No severe organ function impairment
4.Written informed consent of the patient
5.Performance Status 0-2
1.Pregnancy or lactation
2.Decision of unsuitableness by principal investigator
3.Patient with severe underlying disease
4.Patient with severe allergy disease
9
1st name | |
Middle name | |
Last name | Masakazu Yamamoto |
Tokyo Women's Medical University
Department of Gastroenterological Surgery
8-1 Kawada-cho, Shinjyuku-ku, Tokyo
1st name | |
Middle name | |
Last name | Yoshihito Kotera |
Tokyo Women's Medical University
Department of Gastroenterological Surgery
8-1 Kawada-cho, Shinjuku-ku. Tokyo
Tokyo Women's Medical University
Department of Gastroenterological Surgery, Tokyo Women's Medical University
Self funding
Human Genome Center, Institute of Medical Science, The University of Tokyo
NO
東京女子医科大学病院(東京都)
2010 | Year | 10 | Month | 06 | Day |
Unpublished
Completed
2009 | Year | 01 | Month | 10 | Day |
2009 | Year | 01 | Month | 01 | Day |
2010 | Year | 10 | Month | 06 | Day |
2012 | Year | 10 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005192
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |